Measles, mumps and rubella vaccine - Cadila Healthcare

Drug Profile

Measles, mumps and rubella vaccine - Cadila Healthcare

Alternative Names: MMR vaccine - Cadila Healthcare

Latest Information Update: 19 Aug 2016

Price : $50

At a glance

  • Originator Cadila Healthcare
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Measles; Mumps; Rubella

Most Recent Events

  • 11 Apr 2016 Cadila Healthcare completes a phase III trial for Measles, Mumps and Rubella (In infants, Prevention) in India (SC) before April 2016 (CTRI/2015/05/005784)
  • 31 Jan 2014 Phase-II clinical trials in Rubella (prevention in infants) in India (SC)
  • 31 Jan 2014 Phase-II clinical trials in Mumps (prevention in infants) in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top